KZA
Director Trades
| Date | Director | Value |
|---|
Company News
Kazia Therapeutics reveals 100% response rate in interim data from brain metastases drug trial
Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has presented promising new data from an ongoing phase one clinical trial of its lead drug paxalisib in combination with radiotherapy for the treatment of brain metastases. Interim data from the first stage of the study, led by Dr Jonathan Yang at the Memorial Sloan Kettering Cancer Centre […]
‘World-leading’ brain cancer experts headline Kazia Therapeutics’ new scientific advisory board
Kazia Therapeutics (ASX: KZA) has launched a new scientific advisory board (SAB) consisting of “world-leading experts” in developing therapies for brain cancer. Sydney-based oncology-focused Kazia will lean on SAB’s guidance in progressing lead candidate paxalisib towards completion of GBM AGILE studies in the second half of CY2023, followed by commercialisation. Kazia chief executive officer Dr […]
Kazia Therapeutics awarded US FDA rare drug designation for paxalisib in childhood brain cancer
Kazia Therapeutics’ (ASX: KZA) lead drug candidate paxalisib has been awarded rare paediatric disease designation (RPDD) for the treatment of a highly-aggressive childhood brain cancer known as atypical rhabdoid teratoid tumour (AT/RT). The designation was handed down by the US Food and Drug Administration (FDA) and means Kazia may be entitled to receive a paediatric […]
Kazia Therapeutics reports good half-year progress despite market challenges
Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first six months of the year with pipeline assets paxalisib and EVT801 despite a challenging equity market for biotech companies. A phase I study of novel drug EVT801 in patients with advanced cancer continued to recruit well. The drug recently completed the […]
Kazia Therapeutics collars US FDA orphan drug designation for paxalisib in a highly aggressive childhood brain cancer
Kazia Therapeutics (ASX: KZA) has collared orphan drug designation (ODD) from the United States Food and Drug Administration for its lead candidate paxalisib in treating a rare and highly aggressive childhood brain cancer. The ODD is specifically for paxalisib in treating atypical rhabdoid/teratoid tumours (AT/RT), and as part of the designation, the FDA will waive […]
Kazia Therapeutics presents ‘positive data’ on paxalisib in childhood brain cancers
“Positive data” is being presented regarding the activity of Kazia Therapeutics’ (ASX: KZA) lead drug paxalisib in two forms of childhood brain cancers. The company is presenting the data via two presentations this week at the 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) in Germany. Johns Hopkins University’s Dr Jeffrey Rubens spoke about the activity […]
Kazia Therapeutics expands paxalisib study to include secondary brain tumours from breast cancer
Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) is expanding a phase two study of its drug paxalisib in patients with brain metastases to include those starting from breast cancer. The genomically-guided study, led by the US-based cancer research network Alliance for Clinical Trials in Oncology, is evaluating multiple therapies in patients with brain metastases, which […]
Kazia Therapeutics adds recruitment sites to paxalisib arm of global glioblastoma study
Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has confirmed the multi-drug platform study GBM AGILE has opened recruitment to its paxalisib arm in Europe. GBM AGILE is a global, academic-led study designed to identify promising new therapies for glioblastoma, which is the most common and most aggressive form of primary brain cancer in adults. […]
Kazia Therapeutics establishes ‘at-the-market’ equity program
Oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has established an ‘at-the-market’ (ATM) equity program, appointing US-based investment bank Oppenheimer & Co Inc as the sales agent. Under the program, the drug developer may offer and sell via Oppenheimer up to US$35 million of its ordinary shares in the form of American depository shares (ADS), with […]
Kazia Therapeutics completes phase II trial of paxalisib in glioblastoma
Kazia Therapeutics (ASX: KZA) is preparing to present the results of a phase II study evaluating its lead drug paxalisib in glioblastoma, which is the most aggressive form of brain cancer. The phase II study is now complete, and Kazia has the report, with chief executive officer Dr James Garner saying the company was looking […]
